Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process

Vascular injury, activation of the coagulation system and thrombosis are common initial events in the accelerated atherosclerotic process. The role of thrombin generated at the site of aortic injury in the subsequent neointimal proliferation was studied in rabbits (n = 16) 3 weeks after balloon catheter injury. In half of these animals, potent thrombin antagonists, r-hirudin and P-PACK, were administered to prevent acute thrombotic events. Compared to aortas with intact endothelium (n = 8), aortas de-endothelialised 21 days earlier showed neointimal hyperplasia as measured by the intimal/medial ratio (0.68 vs. 0.04, injured vs. normal aortas) and an increase in both total cholesterol (4.08 vs. 3.31 mg/g, p < 0.05) and lipid peroxide content (31.3 vs. 1.1 nmol/g; p < 0.001). Neointimal hyperplasia following endothelial denudation was inhibited in rabbits treated with thrombin-antagonists (0.27 vs. 0.68, treated vs. untreated, p = 0.012) and neither total cholesterol (3.48 mg/g) nor lipid peroxide content (1.5 nmol/g) differed significantly from that of intact arteries. By demonstrating a strong relationship between thrombin generation following de-endothelialisation and the progressive intimal proliferation, this study supports the hypothesis that thrombin is an important contributor to restenosis after vascular injury. The highly atherogenic lipid peroxidation seems to be linked to the early, thrombin-mediated events, as it was completely prevented by adequate thrombin antagonism.

Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.

El resumen se deja sin traducir para conservar la redacción original de los autores.

In rabbit aortas, balloon denudation caused neointimal hyperplasia and rises in cholesterol and lipid peroxides; the thrombin antagonists r-hirudin and P-PACK reduced hyperplasia (intimal/medial ratio 0.27 vs 0.68) and prevented the lipid peroxide rise.

Explore cómo esta investigación se conecta con la práctica clínica

Más estudios revisados por pares en la categoría «Desarrollo de fármacos».

• Hirudoterapia en medicina y odontología — Jha K et al. (2015)
• Terapia con sanguijuelas: una historia — Hyson J (2005)
• Hirudinas de la sanguijuela medicinal asiática Hirudinaria manillensis: iguales, pero diferentes — Lukas P et al. (2019)
• Transcriptomic analysis of the salivary gland of medicinal leech Hirudo nipponia — Lu Z et al. (2018)
• Molecular dynamic and pharmacological studies on protein-engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis — Sun Y et al. (2022)
• Síntesis acelular de la variante 1 de hirudina de la sanguijuela hematófaga Hirudo medicinalis — Wüstenhagen D et al. (2020)
• Producción de variantes de hirudina mediante fábricas microbianas modificadas genéticamente — Zhang J, Lan N (2018)
• Hirudina en la trombocitopenia inducida por heparina — Lubenow N, Greinacher A (2002)
• La hirudina mejora la nefropatía diabética al inhibir la piroptosis mediada por Gsdmd — Han J et al. (2023)
• La hirudina como anticoagulante alternativo: una revisión histórica — Markwardt F (2002)

Ver toda la investigación analizada por la ASH →